The CBO says Trump’s proposed NIH funding cuts and longer FDA review times could significantly reduce the number of new drugs entering the U.S. market.
Drug Innovation At Risk By Trump Budget, Says Congressional Budget Office
Where Today's News Shapes Tomorrow
